Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
3SBio Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
3SBio has been growing earnings at an average annual rate of 13%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 10.3% per year. 3SBio's return on equity is 10.1%, and it has net margins of 19.7%.
Anahtar bilgiler
13.0%
Kazanç büyüme oranı
14.1%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.0% |
| Gelir büyüme oranı | 10.3% |
| Özkaynak getirisi | 10.1% |
| Net Marj | 19.7% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 26
Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being
Jun 19There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now
Jan 26These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely
Dec 30Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Dec 11Is 3SBio (HKG:1530) A Risky Investment?
Sep 12Calculating The Fair Value Of 3SBio Inc. (HKG:1530)
Aug 07With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case
Jul 193SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
Apr 13Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Feb 27Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?
Jan 17Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?
Nov 24We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Oct 213SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate
Oct 04Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?
Apr 21We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Mar 31We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Dec 09An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued
Nov 21We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 103SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate
Aug 223SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?
Mar 11Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 18
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued
Jan 31A Look At 3SBio's (HKG:1530) Share Price Returns
Jan 03Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?
Dec 16What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?
Dec 01Gelir ve Gider Dağılımı
3SBio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 8,422 | 1,659 | 3,693 | 964 |
| 31 Mar 24 | 8,119 | 1,604 | 3,590 | 880 |
| 31 Dec 23 | 7,816 | 1,549 | 3,487 | 795 |
| 30 Sep 23 | 7,686 | 1,739 | 3,351 | 750 |
| 30 Jun 23 | 7,549 | 1,929 | 3,205 | 705 |
| 31 Mar 23 | 7,204 | 1,922 | 3,085 | 699 |
| 31 Dec 22 | 6,866 | 1,916 | 2,974 | 694 |
| 30 Sep 22 | 6,618 | 1,817 | 2,849 | 699 |
| 30 Jun 22 | 6,369 | 1,719 | 2,725 | 703 |
| 31 Mar 22 | 6,376 | 1,685 | 2,710 | 729 |
| 31 Dec 21 | 6,382 | 1,651 | 2,696 | 754 |
| 30 Sep 21 | 6,191 | 1,342 | 2,688 | 717 |
| 30 Jun 21 | 6,000 | 1,032 | 2,681 | 681 |
| 31 Mar 21 | 5,794 | 934 | 2,577 | 636 |
| 31 Dec 20 | 5,588 | 836 | 2,472 | 590 |
| 30 Sep 20 | 5,479 | 1,095 | 2,535 | 581 |
| 30 Jun 20 | 5,370 | 1,355 | 2,598 | 571 |
| 31 Mar 20 | 5,344 | 1,164 | 2,612 | 549 |
| 31 Dec 19 | 5,318 | 974 | 2,627 | 527 |
| 30 Sep 19 | 5,185 | 1,029 | 2,409 | 549 |
| 30 Jun 19 | 5,053 | 1,084 | 2,190 | 572 |
| 31 Mar 19 | 4,818 | 1,181 | 2,099 | 468 |
| 31 Dec 18 | 4,584 | 1,277 | 2,008 | 363 |
| 30 Sep 18 | 4,393 | 1,167 | 1,911 | 181 |
| 30 Jun 18 | 4,202 | 1,057 | 1,814 | 0 |
| 31 Mar 18 | 3,968 | 996 | 1,731 | 0 |
| 31 Dec 17 | 3,734 | 935 | 1,648 | 0 |
| 30 Sep 17 | 3,467 | 877 | 1,601 | 0 |
| 30 Jun 17 | 3,199 | 818 | 1,555 | 0 |
| 31 Mar 17 | 2,998 | 766 | 1,437 | 0 |
| 31 Dec 16 | 2,797 | 713 | 1,318 | 0 |
| 30 Sep 16 | 2,492 | 642 | 1,104 | 0 |
| 30 Jun 16 | 2,188 | 571 | 889 | 0 |
| 31 Mar 16 | 1,930 | 548 | 800 | 0 |
| 31 Dec 15 | 1,673 | 526 | 710 | 0 |
| 30 Sep 15 | 1,503 | 456 | 676 | 0 |
| 30 Jun 15 | 1,364 | 341 | 744 | 0 |
| 31 Mar 15 | 1,247 | 316 | 673 | 0 |
| 31 Dec 14 | 1,131 | 292 | 602 | 0 |
| 30 Sep 14 | 1,044 | 238 | 581 | 0 |
| 31 Dec 13 | 875 | 96 | 439 | 0 |
Kaliteli Kazançlar: 1530 has high quality earnings.
Büyüyen Kar Marjı: 1530's current net profit margins (19.7%) are lower than last year (25.5%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 1530's earnings have grown by 13% per year over the past 5 years.
Büyüme Hızlandırma: 1530's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: 1530 had negative earnings growth (-14%) over the past year, making it difficult to compare to the Biotechs industry average (13.8%).
Özkaynak Getirisi
Yüksek ROE: 1530's Return on Equity (10.1%) is considered low.